Difference between revisions of "Team:Uppsala/Reporter System/UnaG"
Melissajoe (Talk | contribs) |
Melissajoe (Talk | contribs) |
||
| Line 226: | Line 226: | ||
<div> | <div> | ||
| − | <h1>UnaG | + | <h1>UnaG</h1> |
<p>Below we present the changes (improvements i.e.) made to the pre-existing biobrick submitted by the 2016 Uppsala team together with a comparison of the results obtained from expressing and extracting the two UnaG variants. In short, we demonstrate how we obtained a fully working HIS-tag as well as a slightly higher level of expression of UnaG from plasmid.</p> | <p>Below we present the changes (improvements i.e.) made to the pre-existing biobrick submitted by the 2016 Uppsala team together with a comparison of the results obtained from expressing and extracting the two UnaG variants. In short, we demonstrate how we obtained a fully working HIS-tag as well as a slightly higher level of expression of UnaG from plasmid.</p> | ||
| − | < | + | |
| − | + | <h2>Design and Experiment</h2> | |
| + | <h3>Design of UnaG</h3> | ||
| + | <img src="https://static.igem.org/mediawiki/2018/e/e8/T--Uppsala--UnaGSequence.PNG" class="center" > | ||
<br> | <br> | ||
<div class="inner-card-text"> | <div class="inner-card-text"> | ||
| Line 237: | Line 239: | ||
<br> | <br> | ||
<p> Note that we expressed both our modified composite part and the part from 2016 in a pUCIDT (Amp) backbone, which is a low copy plasmid backbone with ampicillin resistance. </p> | <p> Note that we expressed both our modified composite part and the part from 2016 in a pUCIDT (Amp) backbone, which is a low copy plasmid backbone with ampicillin resistance. </p> | ||
| + | |||
| + | <h3>Transforming the Plasmid</h3> | ||
| + | <p>When the plasmids were received from IDT they were transformed into BL21 <i>E. coli</i> cells graciously provided to us by the Forster Laboratory. Same-day-made competent cells using the protocol "Making CaCl2 competent <i>E.coli</i> cells" were used to provide maximum transformation efficiency. </p> | ||
| + | <br> | ||
| + | <h2>Extraction of UnaG</h2> | ||
| + | <p>The protocol for the extraction of our integral membrane protein from the transformed BL21 cells proceeded as described in Materials/Procedure. Note that this was done for both iGEM 2016 cells transformed with the previous part (nicknamed “bad”) and our repositioned start codon (graced with the moniker “good”). </p> | ||
| + | <br> | ||
| + | <h3>Materials/Procedure</h3> | ||
| + | <br> | ||
| + | <ul> | ||
| + | <li><b>Lysis Buffer:</b> PBS solution with 1mM EDTA, 5% glycerol, and 20mM Tris, pH7.4</li> | ||
| + | <li><b>Elution Buffer:</b> 20 mM sodium phosphate, 0.5 M NaCl, 0.5 M imidazole, pH 7.4, 5% glycerol | ||
| + | PBS, 1mM EDTA, 5% glycerol, 20mM Tris, pH7.4</li> | ||
| + | <li><b>Binding/Washing Buffer:</b>0.5 M NaCl, 2 EDTA-free tablets, 10 % glycerol, 20mM sodium phosphate, 1% Triton x100, pH 7.4 (400 mL total)</li> | ||
| + | <li><b>Binding/washing buffer</b> with 1% triton x-100 by weight</li> | ||
| + | </ul> | ||
| + | <br> | ||
| + | <p>Cells were centrifuged at 4000 g 25 minutes at 4 degrees Celsius and then resuspended in Lysis buffer. Cells were lysed using cell disruption with a french press. The now lysed cells were then centrifuged again at at 4000 g 25 minutes at 4 degrees Celsius. The pellet was resuspended in 20mL binding/washing buffer with 1% triton x-100. The solution was incubated on ice for one hour before another round of centrifugation at the same temperature and speed. After centrifugation the supernatant should contain the protein of interest. Bilirubin tests were conducted on both solutions of the pellet and supernatant to observe any fluorescence under a UV light. </p> | ||
| + | <br> | ||
| + | <p>Affinity chromatography was then performed on both “good” and “bad” parts' solutions using prepacked “His-Gravitrap” Columns from GE Healthcare. The protocol for use was performed according to GE healthcare’s specifications, with modified binding/washing/elution buffers. After affinity chromatography, the resulting elutants were tested for fluorescence with a bilirubin test. </p> | ||
| + | |||
| + | |||
</div> | </div> | ||
| Line 251: | Line 275: | ||
<div class="card-holder"> | <div class="card-holder"> | ||
| − | <h1> | + | <h1>Result</h1> |
<p> Cell lysis and affinity chromotography were used to extract UnaG from our cells. Bilirubin tests (addition of a small amount of bilirubin to samples) allowed us to see if the UnaG was present in our samples, since as mentioned earlier UnaG fluoresces in the presence of bilirubin. </p> | <p> Cell lysis and affinity chromotography were used to extract UnaG from our cells. Bilirubin tests (addition of a small amount of bilirubin to samples) allowed us to see if the UnaG was present in our samples, since as mentioned earlier UnaG fluoresces in the presence of bilirubin. </p> | ||
| Line 322: | Line 346: | ||
<div> | <div> | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
Revision as of 22:07, 17 October 2018
UnaG
Below we present the changes (improvements i.e.) made to the pre-existing biobrick submitted by the 2016 Uppsala team together with a comparison of the results obtained from expressing and extracting the two UnaG variants. In short, we demonstrate how we obtained a fully working HIS-tag as well as a slightly higher level of expression of UnaG from plasmid.
Design and Experiment
Design of UnaG
Figure 1. Our annotated modified UnaG sequence with an N-terminal his tag. The terminator, RBS, and promoter sequences were all obtained from the iGEM website. The UnaG gene was taken from the iGEM website and only the start codon was moved so that the gene would properly express with a histidine tag. The start codon was previously immediately after the histidine tag. Note that two plasmids were designed, one using the original UnaG part from the iGEM 2016 Uppsala team and one modified one as shown above. The only modification between the two plasmids is the repositioned start codon. Our composite part and basic part can both be found on the iGEM registry site.
Note that we expressed both our modified composite part and the part from 2016 in a pUCIDT (Amp) backbone, which is a low copy plasmid backbone with ampicillin resistance.
Transforming the Plasmid
When the plasmids were received from IDT they were transformed into BL21 E. coli cells graciously provided to us by the Forster Laboratory. Same-day-made competent cells using the protocol "Making CaCl2 competent E.coli cells" were used to provide maximum transformation efficiency.
Extraction of UnaG
The protocol for the extraction of our integral membrane protein from the transformed BL21 cells proceeded as described in Materials/Procedure. Note that this was done for both iGEM 2016 cells transformed with the previous part (nicknamed “bad”) and our repositioned start codon (graced with the moniker “good”).
Materials/Procedure
- Lysis Buffer: PBS solution with 1mM EDTA, 5% glycerol, and 20mM Tris, pH7.4
- Elution Buffer: 20 mM sodium phosphate, 0.5 M NaCl, 0.5 M imidazole, pH 7.4, 5% glycerol PBS, 1mM EDTA, 5% glycerol, 20mM Tris, pH7.4
- Binding/Washing Buffer:0.5 M NaCl, 2 EDTA-free tablets, 10 % glycerol, 20mM sodium phosphate, 1% Triton x100, pH 7.4 (400 mL total)
- Binding/washing buffer with 1% triton x-100 by weight
Cells were centrifuged at 4000 g 25 minutes at 4 degrees Celsius and then resuspended in Lysis buffer. Cells were lysed using cell disruption with a french press. The now lysed cells were then centrifuged again at at 4000 g 25 minutes at 4 degrees Celsius. The pellet was resuspended in 20mL binding/washing buffer with 1% triton x-100. The solution was incubated on ice for one hour before another round of centrifugation at the same temperature and speed. After centrifugation the supernatant should contain the protein of interest. Bilirubin tests were conducted on both solutions of the pellet and supernatant to observe any fluorescence under a UV light.
Affinity chromatography was then performed on both “good” and “bad” parts' solutions using prepacked “His-Gravitrap” Columns from GE Healthcare. The protocol for use was performed according to GE healthcare’s specifications, with modified binding/washing/elution buffers. After affinity chromatography, the resulting elutants were tested for fluorescence with a bilirubin test.
Result
Cell lysis and affinity chromotography were used to extract UnaG from our cells. Bilirubin tests (addition of a small amount of bilirubin to samples) allowed us to see if the UnaG was present in our samples, since as mentioned earlier UnaG fluoresces in the presence of bilirubin.
Figure 2. Bilirubin test before/after affinity chromatography. Going from left to right the samples are: Lysed sample of the “bad” part before AC, Lysed sample of the “good” part before AC, "Bad" part after AC, "Good" part after AC.
UnaG can be observed in all tubes except the third one, which should not have a histidine tag since we used the 2016 part that was on the iGEM registry and therefore it should not bind in the IMAC column. This supports our claim that our new part functions and provides a histidine tag to the protein, and the old part did not.
Figure 3. Comparison of blank tube to successful extraction/previous iGEM part. The tubes reading from left to right are as followed: Blank tube with AC elution buffer/bilirubin, Tube with bilirubin + AC-eluted original iGEM UnaG part, Our extracted modified UnaG with a moved start codon, as can be seen in Figure 1. Photographed under 312 nm UV-light.
A good degree of fluorescence can be seen in the last tube compared to the other two, which clearly contain none of our protein of interest.
Figure 4. SDS-PAGE gel after affinity chromatography. The first lane corresponds to the good part after AC and the second line corresponds to the bad part after AC. The marked band shows that there's protein that has a size that is close to 16 kDa, while it can't be seen in lane 2.
UnaG is approximately 15.6 kDa, showing that it is indeed in the extracted sample. Other proteins are shown, and this is likely because we used no imidazole in the initial running buffer, leading to unspecific binding. We did this to ensure that we obtained as much UnaG as possible in our sample so that we could conduct fluorescence tests visible by the naked eye.
Figure 5.Fluorescence measurement of unlysed cells. From left to right: Bacterial strain BL21 transformed with a plasmid containing Part:BBa_K2669000 from 2018, Bl21 transfected with Part:BBa_K2003011 from 2016 and normal BL21 cells, all at the same OD600 value. The measurements were conducted with excitation wavelength 448 nm emission wavelength 527 nm.
Figure 6.The supernantant of lysed cells before and after the "His Gravitrap" affinity chromotography. Because of our lysis method UnaG was suspended in the supernatant of the cell cultures. The left samples are supernantant containing the UnaG-protein from 2016 and the right samples are the supernantant containing our UnaG-protein (2018). The measurements were conducted with excitation wavelength 448 nm emission wavelength 527 nm.
Conclusion
With the above experiments, we have shown that we successfully modified the 2016 UnaG part to maintain proper functionality while adding in a constiative promoter + RBS + double terminator.
We have also shown that we have improved the “Inducible Green Fluorescent Protein UnaG+6xHis-tag+Flexible linker” protein part from the iGEM website by making it properly express a histidine tag that allows it to be extracted in affinity chromatography. This is shown in figures 3 and 4. In addition, we have also shown that we have an increased yield for UnaG than the previous iGEM part as can be seen in figure 5. Figure 6 shows that even using the plate reader there is little to no UnaG present in the 2016 sample after IMAC, which suggests a histidine tag was not expressing. The combination of fluorescence after IMAC purification and the correct sized band on the gel proves our biobrick part functions as intended. In addition, we developed a simple protocol to extract membrane proteins, which are traditionally notoriously difficult to extract.
The usage of the Triton X-100 incubation step theoretically created micelles in the solution, allowing membrane fragments to float around and protect UnaG since it is a beta barrel integral membrane protein that is quite hydrophobic in nature (Kumagai A, 2013). It was also found in the literature that using 5-10% glycerol [2] in all solutions involved in the extraction of integral membrane proteins is advised and theoretically helps keep them stabilized.
It may have been beneficial to express UnaG in a low copy plasmid, which might have lessened the risk that these heterologous proteins would conglomerate. We also chose to express UnaG in a constitutive manner, since we previously had no trouble expressing RFP or GFP (proteins with similar structures and environments) constitutively. This saved us time and also provided one less “moving part” that could go wrong in our experiment, such as an induction system not working properly.
References
[1] Kumagai A, Ando R, Miyatake H, Greimel P, Kobayashi T, Hirabayashi Y,
Shimogori T, Miyawaki A. 2013. A Bilirubin-Inducible Fluorescent Protein from Eel Muscle. Cell 153: 1602–1611.
[2] Patel H, Tsamaloukas A, Heerklotz H. The Effect Of Glycerol On Membrane Solubilization By Nonionic
Surfactants. Biophysics 96: 163A-164A
[3] Bowen R. Microbial Life in the Digestive Tract. online: http://www.vivo.colostate.edu/hbooks/pathphys/digestion/basics/gi_bugs.html. Accessed October 12, 2018.
[4] Engineering a palette of eukaryotic chromoproteins for bacterial synthetic biology | Journal of Biological Engineering | Full Text. online: https://jbioleng.biomedcentral.com/articles/10.1186/s13036-018-0100-0. Accessed October 12, 2018.